At $850,000, price for new childhood blindness gene therapy four times too high, nonprofit says

(By Andrew Joseph for STAT)

The $850,000 list price for a new medicine that treats a genetic form of childhood blindness is about four times too high for the value the drug provides, a nonprofit that studies the cost effectiveness of new drugs said Friday, though it added that the price of the drug is cost-effective for select patients and with certain assumptions. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.